Current Research Grants
Visit Ranjit Bindra's Academic Profile
| Agency | Grant Name | Agency Number |
|---|---|---|
| Lion Heart Fund | Exploiting HR defects in Breast Cancer with DNA-PK Inhibitor-Based Therapies | |
| NIH/NICHD | Drug delivery system for enhancing radiation therapy in pediatric glioma | R21 HD090503 |
| Cybrexa Therapeutics | In vivo validation of peptide-drug conjugates | |
| Oligo Nation/Cure | Targeting IDH1/2-mutant gliomas with the potent, CNS-permeable PARP inhibitor, BGB-290 | |
| The Hope Foundation/SWOG | Identification and characterization of oncometabolite-induced DNA repair defects in sporadic papillary kidney cancer | |
| CureSearch for Children’s Cancer | Exploiting Mutant IDH1/2-induced DNA Repair Defects in Pediatric Glioma | |
| Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF) | Small-molecule Screening for Novel Pediatric Glioma Radiosensitizers | |
| YCCI Just-in time Small Pilot Grants Utilizing Core Technologies | Development of Novel Methods to Assess DNA Repair Status in Primary Cell Culture Using Next Generation Sequencing | |
| Joanna McAfee Childhood Cancer Foundation | Creation of Inducible PAX3/7- FOXO1 Cell Lines for Synthetic Lethal Screening Studies | |
| YCC Pilot | High-throughput Screening for K-ras Mutant Cell Tumor Radiosensitizers | |
| YCCC T-TARE | DNA Damage Response: The Achilles Heel of HPV-associated HNSCC | |
| The Cure Starts Now/DIPG Collaborative | Pre-clinical Development of Novel DIPG Radiosensitizers | |
| Matthew Larson Foundation | Creation of Isogenic Pediatric Glioma Cell Lines for High-Throughput Drug Screening Campaigns | |
| NIH/NCI | Development of a Novel Assay to Measure DSB Repair at Endogenous Loci in Cells | 1 R03 CA194967-01 |
| Yale SPORE in Lung Cancer | High-throughput screening for K-Ras mutant tumor cell radiosensitizers | |
| American Cancer Society-Research Scholar Grant | Pre-clinical Development of Mibefradil as a Novel Glioma Radiosensitizer | 128352-RSG-15-197-01-TBG |
| Yale Cancer Center | Nanoparticle-Encapsulated Radiosensitizers for the Treatment of Glioblastoma Multiforme | |
| Musella Foundation | Nanoparticle-Encapsulated Radiosensitizers for the Treatment of Glioblastoma Multiforme | |
| The Pablove Foundation | Small Molecule Screening for Novel Rhabdoid Tumor Inhibitors | |
| NIH/NCI | Exploiting Mutant IDH1/2-Induced Homologous Recombination Defects in Cancer | RO1 CA215453 |
| CureSearch for Children's Cancer | Identification of Novel Targeted Agents for Alveolar Rhabdomyosarcoma | |
| Yale Cancer Center 2017- co- Pilot | Exploitation of 2-HG conferred vulnerabilities in IDH1/2 mutant MDS/AML in pre-clinical PDX models | |
| Alex’s Lemonade Stand Foundation – Innovation Award | Development of nanoparticle-encapsulated chemo/radio-sensitizers for intrathecal delivery | |
| Leukemia and lymphoma Society – Translational Research Program | Exploiting mutant IDH1/2-induced BRCAness with PARP inhibitors as a novel AML/MDS therapy |
Visit Douglas Brash's Academic Profile
| Agency | Grant Name | Agency Number |
|---|---|---|
| DOD | UVL, ROS, Pigmentation, Genetic Predisposition, and Epigenetic Gene Silencing in Melanoma | W81XWH-10-1-0629 |
| NIH | Yale SPORE in Skin Cancer | 2 P50 CA121674-07 |
| L'Oreal | Controlling Chemiexcitation in the Skin: Exploration of Dark CPD Production in Skin | |
| Leo Foundation | Chemiexcitation in Human Disease | |
| NIH/NIAMS | Chemiexcitation: A New Mode of Skin Disease | R01 AR070851 |
Visit David Carlson's Academic Profile
| Agency | Grant Name | Agency Number |
|---|---|---|
| YCCC | Non-invasive Imaging of Tumor Hypoxia in Non-small Cell Lung Cancer Patients Undergoing Stereotactic Body Radiotherapy | |
| American Cancer Society | Modeling Relative Biological Effectiveness and Oxygen Effects in X-ray, Proton, and Carbon Ion Radiotherapy | IRG-58-012-52 |
| Biomedical Advanced Research and Development (BARDA) within the U.S. Department of Health and Human Services | In Vivo Biodosimetry using Electron Paramagnetic Resonance (EPR) Spectroscopy | HHSO100201100024C |
Visit Zhe Chen's Academic Profile
| Agency | Grant Name | Agency Number |
|---|---|---|
| NCI | Prostate Edema in Permanent Interstitial Brachytherapy | 5 R01 CA134627-03 |
Visit Joseph Contessa's Academic Profile
| Agency | Grant Name | Agency Number |
|---|---|---|
| NIH/NIAID | Targeting STT3A and STT3B to Block Flavivirus Replication | R41 AI134531 |
| ASTRO | Targeting N-Linked Glycosylation to Radiosensitive Malignant Gliomas | |
| YCCI | EGFT: Therapeutic Target and Biomarker in NSCLC | 5 UL1 RR024139-05 |
| NIH | A Bioluminescent Screen for Inhibitors of N-linked Glycosylation | 5 R03 DA033178-02 |
| American Cancer Society Institutional Grant | Targeting N-linked Glycosylation in Non-Small Cell Lung Cancer | ACS #IRG-58-012-56 |
| American Cancer Society Research Scholar Grant | Targeting N-linked Glycosylation in Non-Small Cell Lung Cancer | |
| NIH | Targeted N-linked Glycosylation to Advance Radiation Therapy | 1 R01 CA172391-01A1 |
| NIH | Validation of Quantitative 11C-Erlotinib PET for Imaging EGFR-Mutant Lung Cancer | 1 R01 CA195493-01 |
| Department of Defense | Small Molecule Inhibition of the Oligosaccharyltransferase for the Treatment of Breast Cancer | W81XWH-17-1-0066 |
Visit Roy Decker's Academic Profile
| Agency | Grant Name | Agency Number |
|---|---|---|
| Merck | Evaluation of Vorinostat in Combination with Palliative Radiotherapy for Patients with Stage IV Non-small Cell Lung Cancer | 1 35468 |
| RTOG-Clinical Study | Radiation Therapy Oncology Group | 1 U10-CA21661 |
| SciClone Pharmaceuticals, Inc. | A Phase 2b, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 |
Visit Jun Deng's Academic Profile
| Agency | Grant Name | Agency Number |
|---|---|---|
| NIH/NIBIB | Tracking Organ Doses for Patient Safety in Radiation Therapy | 1 R01 EB022589-01 |
Visit Peter Glazer's Academic Profile
| Agency | Grant Name | Agency Number |
|---|---|---|
| NIH | Hypoxia, DNA Repair and Gene Silencing | 5 R01 ES005775-24 |
| NIH | Cancer Center Support Grant (CCSG) | P30 CA016359-37 |
| NIH | Cell-Penetrating Anti-DNA Antibody for Radiosensitization and Cancer Therapy | 5 R01 CA168733-05 |
| NIH | Bifunctional Antibodies for Melanoma Therapy | 5 RO1 CA177719-03 |
| NIH | In Vivo Genomic Editing of Hematopoietic Cells for HIV Resistance | 5 R01 AI112443-02 |
| NIH | Targeted Correction of the Human CFTR Gene | 5 R01 HL125892-02 |
| Cystic Fibrosis Foundation Therapeutics | Gene Editing Using Nanoparticles with Triplex-Forming PNAs | EGAN15XXO |
| NIH | Yale Cancer Biology Training Grant | 5 T32CA193200-02 |
| PNA Innovations, Inc | Modified PNAs To Develop Gene Editing Therapeutics for Hematopoietic Blood Disorders and Cystic Fibrosis | Sponsored Research Award |
| amfAR, The Foundation for AIDs Research | Targeted Inactivation of Integrated HIV Through Host Cell DNA Repair Pathways | Investment Grant |
| FARF | Use of Triplex-Forming PNAs as a Strategy for Correction of the FA Phenotype | Fanconi Anemia Research Fund Award |
| NIH/NCI | Novel DNA Repair Inhibitors for Cancer Therapy | R35 CA197574-01A1 |
Visit James Hansen's Academic Profile
| Agency | Grant Name | Agency Number |
|---|---|---|
| Radiological Society of North America (RSNA) | Targeting Cancer with Cell Penetrating Anti-DNA Antibody | RR1108 |
| American Cancer Society Institutional Grant | Investigating Lupus Autoantibody-based Cancer Therapy | ACS-IRG #58-012-55 |
| RSNA -Research Scholar Grant | Targeting Glioblastoma with a Lupus Autoantibody | |
| YCC 2014 Pilot | Targeting KRAS Mutant Cancer Cells with a Lupus Anti-guanosine Antibody | |
| YCCI 2014 Scholar Grant | Targeting Cancer with a Lupus Autoantibody | |
| Patrys Limited | Deoxymab for Cancer Therapy |
Visit Ryan Jensen's Academic Profile
| Agency | Grant Name | Agency Number |
|---|---|---|
| V Foundation | Elucidating the Replication Fork Protection Problem Caused by PARP inhibitors in BRCA2-mutated Ovarian Cancers | |
| Abramson Cancer Ctr-UPENN | Defining the molecular mechanisms underlying BRCA2 and RAD51 PARP lesion processing | |
| Women’s Health Research at Yale | Illuminating the BRCA2 Molecular Route to Ovarian Cancer | |
| American Cancer Society Institutional Grant | Biochemical and Genetic Characterization of BRCA2 Sequence Variants | ACS-IRG #58-012-55 |
| Breast Cancer Alliance, INC. (BCA) | Biochemical and Genetic Characterization of BRCA2 Sequence Variants | |
| Women's Health Research at Yale (WHRY) | Biochemical Identification of "BRCAness" in Breast Cancer | |
| Ovarian Cancer Research Fund | A "Cellular Switch" to Modulate BRCA2-Mediated Tumor Progression | |
| American Cancer Society-Research Scholar Grant | Elucidating Cancer Risk in Homology-directed Repair Variants | RSG-17-038-01-01-DMC |
| NIH/NCI | Elucidating Cancer Risk in BRCA2 and RAD51 Variants | R01 CA215990 |
Visit Wu Liu's Academic Profile
| Agency | Grant Name | Agency Number |
|---|---|---|
| The Elsa U. Pardee Foundation | Radiotherapy: Monte Carlo Dosimetry Modeling | |
| Yale Cancer Center | Tumor-Targeted Delivery of Theranostic Gadolinium Nanoparticles |
Visit Ravinder Nath's Academic Profile
| Agency | Grant Name | Agency Number |
|---|---|---|
| NIH (YCC Core) | Cancer Center Core Grant | 3 P30-CA16359-32 |
Visit Abhijit Patel's Academic Profile
| Agency | Grant Name | Agency Number |
|---|---|---|
| ASTRO | Ultrasensitive Measurement of Tumor DNA in Blood as a Biomarker of Radiation Response | JF2011-2 |
| YCCI | Circulating Tumor-Derived DNA as a Biomarker for Cancer Treatment Response | 5 UL RR024139-05 |
| Brozman Foundation | Next-Generation Sequencing for Early Detection of Ovarian Tumor DNA in Blood | |
| American Cancer Society | Assessing Cancer Treatment Response by Measurement of Circulating Tumor-Derived DNA | |
| YCC | Tumor-Derived Circulating Mutant K-ras DNA as a Biomarker for Radiation Response: A Novel Deep Sequencing Approach | |
| YCCI TARE | Tumor DNA in Blood as a Biomarker for Early Detection and Monitoring of Lung Cancer | |
| YCCI - Just-in time Small Pilot Grants Utilizing Core Technologies | Tumor DNA in Blood as a Biomarker for Early Detection and Monitoring of Lung Cancer | |
| YCC Pilot | Early Detection of New or Recurrent Ovarian Cancer Using Mutant Tumor DNA in Blood | |
| LUNGevity | Detection of Early-Stage Lung Cancers via Tumor DNA in Blood | |
| Yale SPORE in Lung Cancer | Non-invasive monitoring of mutations in lung cancer via circulating tumor DNA | |
| NIH/NCI | Circulating DNA as a Marker of Treatment Efficacy and Failure in Lung Cancer | 1 R01 CA197486-01A1 |
| The Honorable Tina Brozman Foundation | Early Detection of Ovarian Cancer via Analysis of Genomic Alterations in DNA & RNA from Multiple Sources of Blood | |
| Department of Defense | Early Detection of Lung Cancer via Tumor DNA Fragments in Blood | W81XWH-16-1-0184 |
| Breast Cancer Alliance, Inc. | Profiling of Circulating Tumor Cells to Identify Targets for Adjuvant Therapy in Metastatic Triple Negative Breast Cancer |
Visit Sara Rockwell's Academic Profile
| Agency | Grant Name | Agency Number |
|---|---|---|
| NIH | DNA Repair in Cancer | 5 P01 CA129186-05 |
| NIH | DNA Repair in Cancer-STIMULUS FUNDS | 3 P01 CA129186-04S2 |
| NIH/NCCR | Clinical and Translational Science Award (YCCI) | UL1 RR 023423 |
Visit Faye Rogers's Academic Profile
| Agency | Grant Name | Agency Number |
|---|---|---|
| NIH/NCI | Role of XPD in DNA Damage Response Pathway Choice | R01 GM126211 |
| NIH | Altered Helical Structures: Repair and Induction of Genomic Instability | 5 K22 CA120049-03 |
| NIH | Altered Helical Structures: Repair STIMULUS FUNDS | 3 K22 CA120049-03S1 |
| Breast Cancer Alliance, INC. (BCA) | Gene Targeted Apoptosis as a Therapeutic Strategy for HER2-Positive Breast Cancer | 278479 |
| YCCC Pilot | Novel Therapeutic Strategy for the Treatment of Herceptin Resistant Breast Cancers | |
| NIH/NCI | Gene-Targeted Apoptosis as a Treatment for HER2- Positive Breast Cancer | 1 R21 CA185192-01A1 |
Visit Joann Sweasy's Academic Profile
| Agency | Grant Name | Agency Number |
|---|---|---|
| NIH-CORE B | DiMaio-DNA Polymerase B & Cellular Transformation | 3 P01 CA16038-36 |
| NIH | Characterization of a DNA Polymerase beta deficient mouse | 5 R01 CA116753-05 |
| NIH | DNA Polymerase Beta and Breast Cancer | 1 R21 CA127097-02 |
| NIH | DNA Repair in Cancer | 1 P01 CA129186-05 |
| Subcontract - USC | DNA Polymerase Fidelity Mechanisms: Theory and Experiment | 5 U19 CA10501-08 |
| NIH | DNA Polymerase Beta And Mutagenesis-Fidelity | 5 R01 CA080830-16 |
| Women's Health Research at Yale | Modeling Breast Cancer Treatment in Humanized Mice | |
| YCC | Modeling Breast Cancer Treatment in Humanized Mice | |
| NIH | DNA Polymerase Beta Variants and Cancer | 5 R01 ES019179-03 |
| NIH-UVM | Structure and Function of DNA Repair Enzymes | 5 P01 CA098993-07 |
| YCCI-TARE | The DNA Repair Landscape of Breast Cancer | |
| NIH | Characterization of a DNA Polymerase Beta Deficient Mouse | 2 R01 CA116753-06A1 |
| NIH | Base-Excision Repair and Autoimmunity | 1 R21 AI097756-01 |
| YCCI-SPIRIT | Uncovering the DNA Repair Landscape in Colon Cancer | |
| NIH | Yale SPORE in Skin Cancer | 2 P50 CA121974-07 |
| NIH/HIAID | The Role of a PARP1 Genetic Variant in Development of Lupus | 1 R21 AI124055-01 |
| NIH | Assessing the Role of the DNA Repair Landscape in Immune Checkpoint Therapy | R21 CA216595 |
| Subcontract – University of Vermont | Structure and Function of DNA Repair Enzymes | P01 CA098993 |
Visit Lynn Wilson's Academic Profile
| Agency | Grant Name | Agency Number |
|---|---|---|
| NCI | Racial Disparities in Clinical Outcomes and the Therapeutic Use of Radiotherapy for Patients with Cutaneous Lymphoma | 1 R03 CA151153-01 |
| Stanford Contract | A Multicancer, Open-Label, Radomized, Phase I/II Study Evaluating the Safety and Efficacy of Low-Dose (12Gy)Total Skin Electron Beam Therapy (TSEBT) Combined with Verinostat versus Low Dose TSEBT Monotherapy in Mycosis Fungodes (MF) | 27136490-50891-B |
Visit James Yu's Academic Profile
| Agency | Grant Name | Agency Number |
|---|---|---|
| American Cancer Society Institutional Research Grant | The PICK Pilot trial: Prostate Intensity Modulated Radiation Therapy versus Cyberknife Health Related Quality of Life (HRQoL) Trial | IRG-58-012-52 |
| YCCI Scholar Award | Stereotactic Radiosurgery for Older Cancer Patients with Early Stage Non-small Cell Lung Cancer: National Patterns of Care and Comparison with Surgery | |
| 21st Century Oncology | Research Gift | |
| PhRMA Foundation | Foundation Quantifying the Benefit of Modern Cancer Therapy for Elderly Patients: A Population Level Measurement | |
| Yale Cancer Center | Reanalyzing the TARGIT-A Trial: A Novel Data Sharing Collaboration |
Visit Zhong Yun's Academic Profile
| Agency | Grant Name | Agency Number |
|---|---|---|
| YCC 2018 Pilot | Understanding cell population dynamics in the hypoxic tumor microenvironment | |
| NIH | Role of Hypoxia in the Regulation of Cancer Cell Differentiation | 5 R01 CA125021-05 |
| NIH | Epigenetic Regulation in Hypoxic Cancer Cells | 1 R01 CA148996-02 |
| YCCI-TARE | Stromal Microenvironment and Regulation of Clonal Expansion of Breast Cancer | |
| AHA | Adiposed Signaling and Cardiomyopathy | 11GRNT7970029 |
| State of CT-STEM Cell Research Grant | Hypoxia and Maintenance of Human Cancer Stem Cells | |
| YCC Pilot | A Genetic Oxygen-Sensing Mouse Model | |
| NIH | Malignant and Radioresistant Nature of Hypoxic Tumor Cells | 1 R01 CA178254-01A1 |
| Lion Heart Fund | A novel genetic model of tumor hypoxia for breast cancer research |
